M.D. Anderson Cancer Center: Multiple Myeloma trials

The registry lists 65 Multiple Myeloma studies with M.D. Anderson Cancer Center as lead sponsor. 7 are open to participants now and 27 have results posted.

Phase 1 22Phase 2 41Phase 3 3No phase 11(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) "PRIME-EMD-PMD"RecruitingNCT07382739Phase 2
• Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple MyelomaRecruitingNCT06207799Phase 2
• Phase I/II Open Label Study of Belumosudil Mesylate Alone, and in Combination With Dexamethasone, in Patients With Relapsed/Refractory Multiple MyelomaRecruitingNCT06105554Phase 1/2
• Post-Transplant Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma PatientsRecruitingNCT05776979Phase 2
• Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological MalignancesRecruitingNCT05092451Phase 1/2
• Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple MyelomaRecruitingNCT05091372Phase 2
• Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic MalignanciesRecruitingNCT05011045
• Daratumumab in Treating Participants With Relapsed Multiple Myeloma After Stem Cell TransplantTerminatedNCT03622775Phase 2Results posted
• Melphalan Hydrochloride in Treating Participants With Newly-Diagnosed Multiple Myeloma Undergoing Donor Stem Cell TransplantationCompletedNCT03417284Phase 1/2Results posted
• Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple MyelomaCompletedNCT02506959Phase 2Results posted
• Pomalidomide, Dexamethasone, and Filgrastim-sndz in Treating Patients With Relapsed or Refractory Multiple MyelomaTerminatedNCT01946152Phase 1/2Results posted
• Thalidomide to Overcome Lenalidomide Resistance After Autologous Hematopoietic Stem Cell Transplantation (HCT)TerminatedNCT01927718Not applicableResults posted
• Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid MalignanciesCompletedNCT01919619Phase 2Results posted
• Intervention for Symptom Burden During Maintenance Therapy for Multiple MyelomaCompletedNCT01793051Phase 2Results posted
• Umbilical Cord Blood-Derived Natural Killer Cells, Elotuzumab, Lenalidomide, and High Dose Melphalan, Followed by Stem Cell Transplant in Treating Patients With Multiple MyelomaCompletedNCT01729091Phase 2Results posted
• Ixazomib Citrate and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple MyelomaCompletedNCT01718743Phase 2Results posted
• Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine ConditioningCompletedNCT01572662Phase 2Results posted
• Lenalidomide/Bortezomib/Dexamethasone & CNTO 328 in Transplant Eligible Newly Diagnosed Multiple Myeloma (MM)CompletedNCT01531998Phase 1/2Results posted
• A Randomized Trial to Compare Busulfan + Melphalan 140 mg/m2 With Melphalan 200 mg/m2 as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation for Multiple MyelomaCompletedNCT01413178Phase 3Results posted
• Prevention of Treatment Induced Neuropathy in Multiple MyelomaCompletedNCT01283997Phase 2Results posted
• High-Dose Gemcitabine, Busulfan and Melphalan With Hematopoietic-Cell Support for Patients With Poor-Risk MyelomaCompletedNCT01237951Phase 2Results posted
• Trial of ID-Specific Donor Vaccinated Lymphocyte Infusion for Patients With Myeloma Relapsing or Failing to Achieve a Complete Remission After an Allogenic TransplantTerminatedNCT01174082Phase 2Results posted
• Lenalidomide and High-Dose MelphalanCompletedNCT01079936Phase 1/2Results posted
• Lenalidomide, Thalidomide and Dexamethasone in Treating Participants With Relapsed or Refractory Multiple MyelomaCompletedNCT00966693Phase 1/2Results posted
• Acupuncture for Chemo-Induced Peripheral NeuropathyCompletedNCT00891618Phase 2Results posted
• Methadone, Morphine, or Oxycodone in Treating Pain in Patients With CancerTerminatedNCT00726830Not applicableResults posted
• Arsenic Trioxide With Ascorbic Acid and Melphalan for Myeloma PatientsCompletedNCT00661544Phase 1/2Results posted
• Trial of Two Stem Cell Doses To Reduce Transplant Induced Symptom BurdenCompletedNCT00651937Phase 2Results posted
• Dalteparin in Preventing DVT in Participants With CancerCompletedNCT00525057Not applicableResults posted
• FM 140 vs FM100 Study in Patients With Multiple MyelomaCompletedNCT00505895Phase 2Results posted
• Velcade, Trisenox, Vitamin C and Melphalan for Myeloma PatientsCompletedNCT00469209Phase 1/2Results posted
• Busulfan Plus Melphalan Conditioning Regimen for Lymphoid Malignancies or Multiple MyelomaCompletedNCT00427765Phase 2Results posted
• Cellular Therapy With Cord Blood CellsCompletedNCT00427557Phase 2Results posted
• Curcumin (Diferuloylmethane Derivative) With or Without Bioperine in Patients With Multiple MyelomaCompletedNCT00113841Not applicableResults posted
• Phase II Study of Salvage Radiation Treatment After B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy for Relapsed Refractory Multiple MyelomaActive, not recruitingNCT05336383Phase 2
• Belantamab Mafadotin Maintenance Therapy After Salvage Autologous Hematopoietic Cell Transplantation in Patients With Relapse Refractory Multiple MyelomaTerminatedNCT05065047Phase 1
• Frequency of Cachexia in Ambulatory Cancer Patients and Psychological Burden in Patients and Their Primary CaregiversActive, not recruitingNCT04090619
• Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT03763162Phase 2
• Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell TransplantActive, not recruitingNCT03622788Phase 1/2
• Study of Lenalidomide/Dexamethasone With Nivolumab and Ipilimumab in Patients With Newly Diagnosed Multiple MyelomaWithdrawnNCT03283046Phase 1
• Decision Aid Website in Helping to Make Decisions About Fertility in Participants With CancerActive, not recruitingNCT03141437Not applicable
• Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic MalignanciesCompletedNCT02960646Phase 1
• Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell TransplantActive, not recruitingNCT02861417Phase 2
• Ascending Dose and Exploratory Expansion Study of DS-3032b, an Oral MDM2 Inhibitor, in Subjects With Relapsed and/or Refractory Multiple MyelomaTerminatedNCT02579824Phase 1
• Elotuzumab and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple MyelomaActive, not recruitingNCT02420860Phase 2
• Carfilzomib/SAHA Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant in MyelomaWithdrawnNCT02114502Phase 2
• Carfilzomib, Bendamustine Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT02095834Phase 1
• Revlimid / All-Trans Retinoic Acid (ATRA) / Dexamethasone in Relapsed/Refractory Multiple MyelomaTerminatedNCT01985477Phase 1
• NK Cells in Cord Blood TransplantationStatus unknownNCT01619761Phase 1
• Combination Therapy of Lenalidomide/Bortezomib/Dexamethasone and Panobinostat in Transplant Eligible New Diagnosed Multiple Myeloma (MM) PatientsCompletedNCT01440582Phase 1
• Filanesib and Carfilzomib in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell LeukemiaCompletedNCT01372540Phase 1
• Panobinostat and Carfilzomib in Treating Participants With Relapsed or Refractory Multiple MyelomaCompletedNCT01301807Phase 1
• Efficacy of NF-kB Inhibition for Reducing Symptoms During Maintenance Therapy in Multiple Myeloma PatientsWithdrawnNCT01269203Phase 2
• Antimicrobial Solution or Saline Solution in Maintaining Catheter Patency and Preventing Catheter-Related Blood Infections in Patients With MalignanciesWithdrawnNCT01101412Phase 1/2
• TMC (Topotecan, Cyclophosphamide and Melphalan) for Multiple MyelomaCompletedNCT01039025Phase 2
• Ex-Vivo Depletion of Myeloma Cells From Peripheral Blood Progenitor Cell GraftsWithdrawnNCT00968396Phase 2
• Inflammatory Cytokines in Symptom Production in Multiple MyelomaCompletedNCT00688168
• Etiology of Multiple Myeloma: A Case-Control StudyStatus unknownNCT00505999
• Bortezomib (Velcade) Post Allogenic Peripheral Blood Stem Cell Transplantation for MyelomaCompletedNCT00504634Phase 2
• Long-Term Follow Up Study for AMD3100 PatientsCompletedNCT00476294
• Pegfilgrastim (Neulasta) for Stem Cell Mobilization in Patients With Multiple MyelomaCompletedNCT00067639Phase 2
• CD8 DLI for Patients With Relapse or Residual Disease Following Allogeneic Stem Cell TransplantationTerminatedNCT00038818Not applicable
• Thalidomide for Multiple MyelomaCompletedNCT00038233Phase 3
• Thalidomide-Dexamethasone for Multiple MyelomaCompletedNCT00038090Phase 2/3
• Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic CancerCompletedNCT00005092Phase 1